A Cognitive-Behavioral Perspective on Avoidance and Acceptance in Psychedelic Therapy | Max Wolff
Dr. Max Wolff | Science Division of the MIND Foundation
https://insight-conference.eu/speaker/max-wolff/
In recent years, several early-phase clinical trials have provided preliminary evidence that psychedelic therapy – treating patients with psilocybin, LSD, or the DMT-containing plant medicine ayahuasca in a carefully controlled setting – is an effective treatment for various mental disorders. Qualitative patient interviews suggest that one way in which psychedelic therapy works is by promoting sustainable transitions from experiential avoidance to acceptance. So far, the psychological mechanisms underlying such change remain largely unclear. In this short talk, I will present a conceptual model that specifies how acute psychedelic ‘belief relaxation’ in combination with the particular context established according to psychedelic therapy protocols may facilitate the same acceptance-promoting learning processes that are also targeted by cognitive-behavioral therapy (CBT) interventions. Open research questions and implications for clinical practice will be discussed.
--------------------
We are a non-profit organisation - but you can support our work with a donation! With your tax-deductible donation we can achieve our goals and visions. Every euro or dollar you donate will fund a project or researcher who is committed to safe and legal therapies, harm reduction and the development of the European health system. Please indicate "Wolf Video" as the intended purpose.
Link: https://mind-foundation.org/donate
----------------------
Max Wolff is a clinical psychologist and addiction researcher at Technische Universität Dresden. His research is concerned with processes of behavioral change, and focuses on self-control failures in everyday life and addictive disorders. As a clinical psychologist he works with cognitive-behavioral therapy and is inclined towards acceptance-based approaches.
Max is an active member of the MIND Foundation’s Science Division. He is involved in research projects about long-term responses to psychedelics and psilocybin-assisted therapy of depression.
Dr. Max Wolff | Science Division of the MIND Foundation
https://insight-conference.eu/speaker/max-wolff/
In recent years, several early-phase clinical trials have provided preliminary evidence that psychedelic therapy – treating patients with psilocybin, LSD, or the DMT-containing plant medicine ayahuasca in a carefully controlled setting – is an effective treatment for various mental disorders. Qualitative patient interviews suggest that one way in which psychedelic therapy works is by promoting sustainable transitions from experiential avoidance to acceptance. So far, the psychological mechanisms underlying such change remain largely unclear. In this short talk, I will present a conceptual model that specifies how acute psychedelic ‘belief relaxation’ in combination with the particular context established according to psychedelic therapy protocols may facilitate the same acceptance-promoting learning processes that are also targeted by cognitive-behavioral therapy (CBT) interventions. Open research questions and implications for clinical practice will be discussed.
——————–
We are a non-profit organisation – but you can support our work with a donation! With your tax-deductible donation we can achieve our goals and visions. Every euro or dollar you donate will fund a project or researcher who is committed to safe and legal therapies, harm reduction and the development of the European health system. Please indicate “Wolf Video” as the intended purpose.
Link: https://mind-foundation.org/donate
———————-
Max Wolff is a clinical psychologist and addiction researcher at Technische Universität Dresden. His research is concerned with processes of behavioral change, and focuses on self-control failures in everyday life and addictive disorders. As a clinical psychologist he works with cognitive-behavioral therapy and is inclined towards acceptance-based approaches.
Max is an active member of the MIND Foundation’s Science Division. He is involved in research projects about long-term responses to psychedelics and psilocybin-assisted therapy of depression.
){kind=link}
Comments